Comparative Analysis of SLCO1B1 Gene Polymorphisms in Dyslipidemic and Normolipidemic Patients with Type 2 Diabetes Mellitus Residing at High Altitude.

IF 2.4 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics & Personalized Medicine Pub Date : 2026-07-27 eCollection Date: 2026-01-01 DOI:10.2147/PGPM.S593658

Yong-Hong Ma, Zong-Hong Ji, Chun-Na Han, Sheng-Hua Ma, Jin-Lan Ma, Rui-Xia Zhang, Zhuo-Ma Ni-Yang, Zhi-Xi Zhao, Qi-Fu Zhang

{"title":"Comparative Analysis of SLCO1B1 Gene Polymorphisms in Dyslipidemic and Normolipidemic Patients with Type 2 Diabetes Mellitus Residing at High Altitude.","authors":"Yong-Hong Ma, Zong-Hong Ji, Chun-Na Han, Sheng-Hua Ma, Jin-Lan Ma, Rui-Xia Zhang, Zhuo-Ma Ni-Yang, Zhi-Xi Zhao, Qi-Fu Zhang","doi":"10.2147/PGPM.S593658","DOIUrl":null,"url":null,"abstract":"Objective: To examine the association between SLCO1B1 gene polymorphisms and blood lipid metabolism in Tibetan patients with type 2 diabetes mellitus (T2DM) in Yushu, Qinghai, China.Methods: A cross-sectional study enrolled 156 Tibetan T2DM patients (78 normolipidemic and 78 dyslipidemic) admitted to Yushu People's Hospital between September 2022 and December 2023. SLCO1B1 521T>C and 388A>G polymorphisms were genotyped using PCR-RFLP.Results: The 521TC genotype frequency was significantly higher in the dyslipidemia group (30.8% vs. 14.1%, p < 0.05), with elevated triglycerides, total cholesterol, and low-density lipoprotein cholesterol (p < 0.01). Multivariate regression confirmed positive associations. The 388AG and 388GG genotypes were associated with elevated triglycerides (p < 0.05).Conclusion: SLCO1B1 521T>C and 388A>G polymorphisms are significantly associated with dyslipidemia in this high-altitude Tibetan T2DM population, with 521T>C showing stronger predictive potential.","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":"19 ","pages":"593658"},"PeriodicalIF":2.4000,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13426349/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics & Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PGPM.S593658","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine the association between SLCO1B1 gene polymorphisms and blood lipid metabolism in Tibetan patients with type 2 diabetes mellitus (T2DM) in Yushu, Qinghai, China.

Methods: A cross-sectional study enrolled 156 Tibetan T2DM patients (78 normolipidemic and 78 dyslipidemic) admitted to Yushu People's Hospital between September 2022 and December 2023. SLCO1B1 521T>C and 388A>G polymorphisms were genotyped using PCR-RFLP.

Results: The 521TC genotype frequency was significantly higher in the dyslipidemia group (30.8% vs. 14.1%, p < 0.05), with elevated triglycerides, total cholesterol, and low-density lipoprotein cholesterol (p < 0.01). Multivariate regression confirmed positive associations. The 388AG and 388GG genotypes were associated with elevated triglycerides (p < 0.05).

Conclusion: SLCO1B1 521T>C and 388A>G polymorphisms are significantly associated with dyslipidemia in this high-altitude Tibetan T2DM population, with 521T>C showing stronger predictive potential.

查看原文本刊更多论文

高海拔地区2型糖尿病血脂异常与正常血脂患者SLCO1B1基因多态性比较分析

目的：探讨青海玉树藏族2型糖尿病（T2DM）患者SLCO1B1基因多态性与血脂代谢的关系。方法：横断面研究纳入2022年9月至2023年12月玉树人民医院收治的156例藏族T2DM患者（78例血脂正常，78例血脂异常）。采用PCR-RFLP方法对SLCO1B1、521T、>、C和388A>、G多态性进行基因分型。结果：521TC基因型频率在血脂异常组显著升高（30.8%比14.1%,p < 0.05），甘油三酯、总胆固醇、低密度脂蛋白胆固醇升高（p < 0.01）。多元回归证实呈正相关。388AG和388GG基因型与甘油三酯升高相关（p < 0.05）。结论：SLCO1B1 521T>C和388A>G多态性与西藏高海拔T2DM人群血脂异常显著相关，其中521T>C具有较强的预测潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics & Personalized Medicine Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

3.30

自引率

5.30%

发文量

110

审稿时长

16 weeks

期刊介绍： Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability. In particular, emphasis will be given to: Genomic and proteomic profiling Genetics and drug metabolism Targeted drug identification and discovery Optimizing drug selection & dosage based on patient''s genetic profile Drug related morbidity & mortality intervention Advanced disease screening and targeted therapeutic intervention Genetic based vaccine development Patient satisfaction and preference Health economic evaluations Practical and organizational issues in the development and implementation of personalized medicine programs.